Patent challenger Natco is now Gilead licensee for Sovaldi
Patent challenger Natco Pharma has made a strategic about turn and has now emerged as a licensee for Gilead Sciences's blockbuster hepatitis C therapy, Sovaldi (sofosbuvir).
Patent challenger Natco Pharma has made a strategic about turn and has now emerged as a licensee for Gilead Sciences's blockbuster hepatitis C therapy, Sovaldi (sofosbuvir).